Vikram Narayan, MD
Urology · Atlanta, GANPI 1336582782
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,103 of the $29,018 with a category attached, or 72.7%. 7 manufacturers reported payments, led by Ferring Pharmaceuticals AS at 47.9% of the total. Reporting peaked in 2022 at $20,984 and has fallen 72.0% since, to $5,883 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $967.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals AS$14K
- Merck$7K
- Ferring Pharmaceuticals Inc.$6K
- Eli Lilly$2K
- Boston Scientific$49
- Coloplast$44
- plus $24 from 1 others
Across 144 payments — averaging $7488.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$541K
- Merck$436K
- Ferring Pharmaceuticals AS$61K
- Photocure Inc$39K
- Organon$975
What the payments were for
- Consulting fees$21,10373%
- Speaking & faculty fees$4,27515%
- Travel & lodging$2,85110%
- Food & beverage$7893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals AS | 10 | $13,891 |
| Merck | 2 | $7,094 |
| Ferring Pharmaceuticals Inc. | 10 | $6,355 |
| Eli Lilly | 3 | $1,562 |
| Boston Scientific | 2 | $49 |
| Coloplast | 2 | $44 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$7,050
- ADSTILADRIN$6,287
How this compares
$29,018 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolterodine Tartrate | 19 | $694 |
| Tamsulosin Hcl | 61 | $425 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $167 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $64 |
| Cephalexin | 11 | $60 |
| Oxybutynin Chloride | 13 | $30 |
Paid to pharmacies, not to this prescriber.
Other urology in Atlanta
- Tariq HakkyAtlanta$140K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Matthew SandAtlanta$77K
- Brendan BrowneAtlanta$53K
- Rajesh LaunganiAtlanta$33K
- Gregory MitchellAtlanta$15K
- Charles LorentzAtlanta$14K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.